Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ligand Provides A 5-Year Outlook; Adjusted Diluted EPS Outlook For 2028 Is In The Range Of $10.00-$10.50; Total Core Revenue Could Reach ~$290M By 2028

Author: Benzinga Newsdesk | December 12, 2023 01:07pm

The company provided an illustrative 5-year outlook, as follows:

Ligand's existing commercial programs, pipeline of mid- to late-stage programs and portfolio of over 75 additional partnerships (the "Pharm Team") are expected to drive five-year growth in royalties at a compounded annual growth rate (CAGR) of 16%.
Layering on the first wave of potential future investments, the five-year CAGR for royalties could increase to above 20%.
Total core revenue could reach approximately $290 million by 2028.
EBITDA margin could exceed 80% by 2028.
Adjusted diluted EPS outlook for 2028 is in the range of $10.00 to $10.50.

Posted In: LGND